Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/21/3/667/399334/mdp563.pdf
Reference5 articles.
1. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer;Wedam;J Clin Oncol,2006
2. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzuamb: updated efficacy and biomarker analyses;Cameron;Breast Cancer Res Treat,2008
3. Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study;Kaufman;Lancet Oncol,2009
4. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens;Blackwell;Ann Oncol,2009
5. Metronomic cyclophoshamide and capecitabine combined with bevacizumab in advanced breast cancer;Dellapasqua;J Clin Oncol,2008
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. NDRG2 regulates adherens junction integrity to restrict colitis and tumourigenesis;EBioMedicine;2020-11
2. Early relapse of inflammatory breast carcinoma treated with lapatinib and capecitabine: Ten years of complete response;The Breast Journal;2019-09-29
3. The toxicity of anti-VEGF agents when coupled with standard chemotherapeutics;Cancer Letters;2015-02
4. Comparative Effectiveness of Two Metronomic Chemotherapy Schedules—Our Experience in the Preclinical Field;Cancer Investigation;2014-02-05
5. Lessons Learned from an Unusual Case of Inflammatory Breast Cancer;Journal of Surgical Education;2012-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3